Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

NovoCure Q4 EPS Misses, Revenue Matches

TheMotleyFool

0 0

Oncology treatment pioneer NovoCure (NASDAQ:NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year over year. However, NovoCure's GAAP EPS loss of $0.61 was worse than the estimated $0.34 loss.

Despite these mixed results, NovoCure achieved significant strides with FDA approvals and positive clinical trial outcomes, indicating promising avenues for growth.

Source: NovoCure. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. EBITDA = Earnings before interest, taxes, depreciation, and amortization.

Source Fool.com